News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
72,961 Results
Type
Article (2938)
Company Profile (256)
Press Release (69762)
Multimedia
Podcasts (15)
Webinars (3)
Section
Business (23880)
Career Advice (52)
Deals (3557)
Drug Delivery (19)
Drug Development (8093)
Employer Resources (32)
FDA (1356)
Job Trends (1734)
News (33765)
Policy (2348)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (7)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
Academia (201)
Accelerated approval (25)
ADA (15)
Adcomms (2)
Allergies (50)
Alliances (2085)
ALS (90)
Alzheimer's disease (285)
Antibody-drug conjugate (ADC) (224)
Approvals (1696)
Artificial intelligence (327)
ASCO (117)
Autoimmune disease (135)
Automation (29)
Bankruptcy (13)
Belgium (1)
Best Places to Work (1881)
BIO (22)
Biologics (4)
BIOSECURE Act (9)
Biosimilars (99)
BioSpace Insights (36)
Biotechnology (169)
Bispecific (1)
Bladder cancer (140)
Brain cancer (13)
Breast cancer (361)
Cancer (2544)
Cardiovascular disease (206)
Career advice (55)
Career pathing (5)
CAR-T (112)
CDC (58)
CDMO (14)
Celiac Disease (1)
Cell therapy (308)
Cervical cancer (27)
Clinical research (10141)
Collaboration (912)
Commercialization (2)
Company closure (2)
Compensation (1001)
Complete response letters (16)
COVID-19 (285)
CRISPR (45)
C-suite (468)
Cystic fibrosis (48)
Data (3466)
Decentralized trials (1)
Denatured (5)
Depression (58)
Dermatology (55)
Diabetes (181)
Diagnostics (975)
Digital health (19)
Diversity (1)
Diversity, equity & inclusion (11)
Drug discovery (140)
Drug pricing (110)
Drug shortages (8)
Duchenne muscular dystrophy (98)
Earnings (22797)
Editorial (26)
Employer branding (3)
Employer resources (21)
Events (9374)
Executive appointments (469)
FDA (3082)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (5)
Frontotemporal dementia (14)
Funding (725)
Gene editing (87)
Generative AI (19)
Gene therapy (226)
GLP-1 (302)
Government (569)
Grass and pollen (3)
Guidances (291)
Healthcare (2063)
Hematology (57)
HIV (75)
Huntington's disease (19)
IgA nephropathy (63)
Immunology and inflammation (63)
Immuno-oncology (40)
Indications (95)
Infectious disease (414)
Inflammatory bowel disease (56)
Inflation Reduction Act (9)
Influenza (34)
Intellectual property (76)
Interviews (7)
IPO (2826)
IRA (34)
Job creations (181)
Job search strategy (40)
JPM (4)
Kidney cancer (13)
Labor market (25)
Layoffs (49)
Leadership (4)
Legal (347)
Licensing (6)
Liver cancer (28)
Longevity (6)
Lung cancer (393)
Lymphoma (199)
Machine learning (28)
Management (6)
Manufacturing (370)
Marketing (6)
MASH (62)
Medical affairs (1)
Medical device (1704)
Medtech (1775)
Mergers & acquisitions (1245)
Metabolic disorders (489)
mRNA (43)
Multiple sclerosis (63)
Multispecific (1)
NASH (4)
Netherlands (2)
Neurodegenerative disease (169)
Neuropsychiatric disorders (45)
Neuroscience (867)
NextGen: Class of 2026 (625)
Non-profit (392)
Now hiring (3)
Obesity (244)
Opinion (31)
Ovarian cancer (87)
Pain (55)
Pancreatic cancer (90)
Parkinson's disease (110)
Partnered (1)
Patents (163)
Patient recruitment (314)
Peanut (16)
People (3053)
Peptides (3)
Pharmaceutical (54)
Pharmacy benefit managers (20)
Phase 1 (2540)
Phase 2 (4060)
Phase 3 (4255)
Pipeline (4692)
Policy (154)
Postmarket research (327)
Preclinical (704)
Press Release (3)
Prostate cancer (157)
Psychedelics (33)
Radiopharmaceuticals (54)
Rare diseases (403)
Real estate (211)
Recruiting (5)
Regulatory (3188)
Reports (39)
Research institute (177)
Resumes & cover letters (4)
Rett syndrome (35)
RNA editing (3)
RSV (49)
Schizophrenia (63)
Series A (113)
Series B (95)
Service/supplier (9)
Sickle cell disease (34)
Special edition (6)
Spinal muscular atrophy (20)
Sponsored (3)
Startups (156)
Stomach cancer (2)
Supply chain (44)
Tariffs (36)
The Weekly (10)
Vaccines (282)
Venture capital (25)
Weight loss (155)
Women's health (59)
Worklife (3)
Date
Today (31)
Last 7 days (190)
Last 30 days (715)
Last 365 days (11086)
2026 (7589)
2025 (11616)
2024 (7175)
2023 (4560)
2022 (5316)
2021 (5377)
2020 (4759)
2019 (3861)
2018 (3070)
2017 (2489)
2016 (2090)
2015 (2559)
2014 (1520)
2013 (980)
2012 (1203)
2011 (1426)
2010 (1163)
Location
Africa (59)
Alabama (19)
Arizona (43)
Arkansas (5)
Asia (4073)
Australia (500)
California (6195)
Canada (1099)
China (452)
Colorado (232)
Connecticut (258)
Delaware (291)
Europe (10254)
Florida (561)
Georgia (141)
Hawaii (5)
Idaho (8)
Illinois (551)
India (29)
Indiana (171)
Iowa (14)
Japan (382)
Kansas (18)
Kentucky (25)
Louisiana (27)
Maine (12)
Maryland (496)
Massachusetts (4414)
Michigan (101)
Minnesota (261)
Mississippi (1)
Missouri (60)
Montana (3)
Nebraska (3)
Nevada (62)
New Hampshire (18)
New Jersey (1471)
New Mexico (8)
New York (1279)
North Carolina (556)
North Dakota (4)
Northern California (3137)
Ohio (180)
Oklahoma (13)
Oregon (9)
Pennsylvania (734)
Puerto Rico (4)
Rhode Island (14)
South America (71)
South Carolina (8)
South Dakota (1)
Southern California (2405)
Tennessee (92)
Texas (903)
United States (19325)
Utah (110)
Vermont (1)
Virginia (154)
Washington D.C. (34)
Washington State (431)
West Virginia (3)
Wisconsin (119)
72,961 Results for "36".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2025
September 7, 2026
·
1 min read
Press Releases
Correction: IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026
September 15, 2026
·
1 min read
Press Releases
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
September 9, 2026
·
9 min read
Press Releases
Theralase(R) Closes C$3.6 Million Brokered Financing
August 24, 2026
·
8 min read
Press Releases
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)
September 7, 2026
·
3 min read
Press Releases
Pilatus Biosciences Strengthens Global Intellectual Property Position for Lead CD36-Targeted Immunometabolic Therapy
September 8, 2026
·
3 min read
Earnings
Denali climbs past Avlayah expectations with $3.6M in revenue
After launching in April, Hunter syndrome drug Avlayah surprised analysts with a strong first quarter, as patients rush to get access to Denali Therapeutics’ new option.
August 10, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
August 10, 2026
·
6 min read
Press Releases
Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
July 5, 2026
·
5 min read
Press Releases
Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
September 8, 2026
·
5 min read
1 of 7,297
Next
